US Bancorp DE Has $556,000 Stock Position in BioNTech SE (NASDAQ:BNTX)

US Bancorp DE lessened its holdings in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 81.8% in the third quarter, according to its most recent filing with the SEC. The firm owned 4,678 shares of the company's stock after selling 21,012 shares during the period. US Bancorp DE's holdings in BioNTech were worth $556,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of BNTX. Candriam S.C.A. grew its holdings in BioNTech by 261.2% during the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company's stock worth $46,526,000 after acquiring an additional 418,695 shares during the period. Point72 Asset Management L.P. grew its holdings in shares of BioNTech by 283.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company's stock valued at $37,103,000 after buying an additional 341,311 shares during the period. abrdn plc grew its holdings in shares of BioNTech by 334.4% in the 3rd quarter. abrdn plc now owns 225,992 shares of the company's stock valued at $26,841,000 after buying an additional 173,969 shares during the period. DekaBank Deutsche Girozentrale grew its holdings in shares of BioNTech by 12.6% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 481,397 shares of the company's stock valued at $56,886,000 after buying an additional 53,800 shares during the period. Finally, Acadian Asset Management LLC grew its holdings in shares of BioNTech by 51.3% in the 1st quarter. Acadian Asset Management LLC now owns 111,398 shares of the company's stock valued at $10,275,000 after buying an additional 37,792 shares during the period. Institutional investors and hedge funds own 15.52% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on BNTX. JPMorgan Chase & Co. decreased their price target on shares of BioNTech from $125.00 to $124.00 and set a "neutral" rating for the company in a report on Monday, November 4th. Hsbc Global Res raised shares of BioNTech from a "hold" rating to a "strong-buy" rating in a report on Friday, August 2nd. Jefferies Financial Group raised shares of BioNTech from a "hold" rating to a "buy" rating and upped their target price for the stock from $96.00 to $150.00 in a research note on Tuesday, September 17th. Deutsche Bank Aktiengesellschaft upped their target price on shares of BioNTech from $95.00 to $150.00 and gave the stock a "buy" rating in a research note on Thursday, September 19th. Finally, Morgan Stanley raised shares of BioNTech from an "equal weight" rating to an "overweight" rating and upped their target price for the stock from $93.00 to $145.00 in a research note on Tuesday, September 24th. Four analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $137.54.

BioNTech Stock Down 1.7 %

Shares of BioNTech stock traded down $1.91 during trading hours on Monday, reaching $108.73. 1,408,645 shares of the company's stock were exchanged, compared to its average volume of 788,114. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The stock has a market cap of $25.85 billion, a P/E ratio of -51.78 and a beta of 0.26. The company has a 50 day moving average of $111.85 and a two-hundred day moving average of $96.66. The company has a current ratio of 7.33, a quick ratio of 7.40 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. During the same period last year, the business posted $0.73 EPS. BioNTech's revenue was up 38.9% on a year-over-year basis. On average, sell-side analysts forecast that BioNTech SE will post -3.47 EPS for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.